Afuco™ Anti-CD4 ADCC Therapeutic Antibody (Clenoliximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (primate/human) antibody expressed in CHO binding to human CD4/p55. Clenoliximab is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-732 |
| Pricing | Inquiry |
| Host | Chimeric |
| Target | CD4 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |